SR

Sanjay Raghavbhai Tavethiya

Active Director Director DIN 03045908
DIN 03045908 First appointment May 2010 Primary industry Chemicals and Materials
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since May 2010
Shareholding value •••• Premium profile

About Sanjay Raghavbhai Tavethiya

Data last updated:

Sanjay Raghavbhai Tavethiya is a Director at Neelgreev Pharmaceutical Private Limited (since 2023), Director at Shreeneel Chemicals Private Limited (since 2021) and Designated Partner at Unity Finechem Llp (since 2024). The companies operate in Chemicals and Materials and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹4.7 Lakh; the largest is Neelgreev Pharmaceutical Private Limited at ₹3.4 Lakh (FY 2025). Earlier, Sanjay Raghavbhai Tavethiya was a Director at Hema Pharmaceuticals Pvt Ltd (2012–2015) and Ceo(Kmp) at Chaitanya Life Science Private Limited (2016–2021) and 1 more.

DIN 03045908
Primary Designation Director
Industry Chemicals and Materials
First Appointment 13 May 2010
Oldest Company Age 16 yrs
Largest company Neelgreev Pharmaceutical Private Limited · ₹3.4 Lakh (FY 2025)
Combined revenue ₹4.7 Lakh across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Jul 20232020₹3.4 Lakh (FY 2025)Active
Shreeneel Chemicals Private Limited U24290GJ2021PTC126875
Director07 Dec 20212021₹1.3 Lakh (FY 2025)Active
Designated Partner22 Feb 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hema Pharmaceuticals Pvt Ltd U24230GJ1988PTC010557
Director22 Oct 20121988₹85.23 Cr (FY 2025)Active
Ceo(Kmp)10 Aug 20162010₹13.59 Cr (FY 2024)Active
Tetrachem Healthcare Private Limited U85100GJ2010PTC060683
Director13 May 20102010Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Tetrachem Healthcare Private Limited
Shreeneel Chemicals Private Limited
Unity Finechem Llp
Neelgreev Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Sanjay Raghavbhai Tavethiya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanjay Raghavbhai Tavethiya

Sanjay Raghavbhai Tavethiya currently holds 3 directorships: Neelgreev Pharmaceutical Private Limited (Director, since 01 Jul 2023, revenue ₹3.4 Lakh (FY 2025)); Shreeneel Chemicals Private Limited (Director, since 07 Dec 2021, revenue ₹1.3 Lakh (FY 2025)); Unity Finechem Llp (Designated Partner, since 22 Feb 2024).

Sanjay Raghavbhai Tavethiya was first appointed on 13 May 2010 as Director at Tetrachem Healthcare Private Limited. The most recent appointment on record is 22 Feb 2024 at Unity Finechem Llp.

The 2 current companies of Sanjay Raghavbhai Tavethiya that report revenue have a combined latest revenue of ₹4.7 Lakh: Neelgreev Pharmaceutical Private Limited ₹3.4 Lakh (FY 2025); Shreeneel Chemicals Private Limited ₹1.3 Lakh (FY 2025).

Sanjay Raghavbhai Tavethiya held 3 earlier board appointments: Hema Pharmaceuticals Pvt Ltd (Director, 22 Oct 2012 to 31 Jul 2015); Chaitanya Life Science Private Limited (Ceo(Kmp), 10 Aug 2016 to 01 Jun 2021); Tetrachem Healthcare Private Limited (Director, from 13 May 2010).

The current boards of Sanjay Raghavbhai Tavethiya's companies include Anoopsingh Tomar (Neelgreev Pharmaceutical Private Limited), Pradeep Singh (Neelgreev Pharmaceutical Private Limited), Nirav Akshaykumar Suthar (Shreeneel Chemicals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available